Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol. Issue 2 (9th February 2022)

• Record Type: Journal Article
• Authors: Sentís, Alexis; Torán, Pere; Esperalba, Juliana; Agustí, Cristina; Ángel Munoz, Miguel; Fernández, Gema; Dopico, Eva; Salvador-González, Betlem; González, Maria Victoria; Bordas, Anna; Antón, Andrés; Violan, Concepció; Montoro-Fernández, Marcos; Aceiton, Jordi; Egea-Cortés, Laia; Alonso, Lucía; Dacosta-Aguayo, Rosalia; Calatayud, Laura; Lejardi, Yolanda; Mendioroz, Jacobo; Basora, Josep; Reyes-Urueña, Juliana; Casabona, Jordi
• Is Part Of: BMJ open. Volume 12:Issue 2(2022)
• Publication Date: 2022-02-09
• Subjects: epidemiology -- primary care -- COVID-19 -- public health; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-053237
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: SARS-CoV-2 seroprevalence studies are currently being recommended and implemented in many countries. Forming part of the COVID-19 monitoring and evaluation plan of the Catalan Government Health Department, our network aims to initiate a primary healthcare sentinel monitoring system as a surrogate of SARS-CoV-2 exposure in the Barcelona Metropolitan Area. Methods and analysis: The seroCAP is a serial cross-sectional study, which will be performed in the Barcelona Metropolitan Area to estimate antibodies against SARS-CoV-2. From February 2021 to March 2022, the detection of serum IgG antibodies against SARS-CoV-2 trimeric spike protein will be performed on a monthly basis in blood samples collected for diverse clinical purposes in three reference hospitals from the three Barcelona healthcare areas (BCN areas). The samples (n=2588/month) will be from patients attended by 30 primary healthcare teams at 30 basic healthcare areas (BHA). A lab software algorithm will systematically select the samples by age and sex. Seroprevalence will be estimated and monitored by age, sex, BCN area and BHA. Descriptive and cluster analysis of the characteristics and distribution of SARS-CoV-2 infections will be performed. Sociodemographic, socioeconomic and morbidity-associated factors will be determined using logistic regression. We will explore the association between seroprevalence, SARS-CoV-2 confirmed cases and the implemented measures using interrupted time series analysis. Ethics and dissemination: Ethical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina ethics committee. An informed consent is not required regarding the approval of the secondary use of biological samples within the framework of the COVID-19 pandemic. A report will be generated quarterly. The final analysis, conclusions and recommendations will be shared with the stakeholders and communicated to the general public. Manuscripts resulting from the network will be submitted for publication in peer-reviewed journals.